Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Oncocyte Corp (OCX)

Oncocyte Corp (OCX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Insider Purchase: Chief Financial Officer of $OCX (OCX) Buys 20,000 Shares Quiver Quantitative, Inc. - Mon Dec 9, 5:22PM CST

Andrea S. James, the Chief Financial Officer of $OCX ($OCX), bought 20,000 shares of the company on 12-05-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This...

OCX : 2.19 (-0.90%)
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings GlobeNewswire - Mon Dec 9, 3:05PM CST

OCX : 2.19 (-0.90%)
Oncocyte Corp. Announces Positive Data for DetermaCNI™ Assay in Diagnosing Central Nervous System Tumors Quiver Quantitative, Inc. - Thu Dec 5, 1:36AM CST

Oncocyte Corp. reports positive findings for DetermaCNI™, a liquid biopsy assay for diagnosing central nervous system tumors.Quiver AI SummaryOncocyte Corp. has announced the publication of positive...

OCX : 2.19 (-0.90%)
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study GlobeNewswire - Wed Dec 4, 3:15PM CST

OCX : 2.19 (-0.90%)
Oncocyte Publishes Pioneering Study Highlighting VitaGraft’s Role in Early Diagnosis of Transplant Rejection Quiver Quantitative, Inc. - Tue Dec 3, 1:20AM CST

Oncocyte's study shows its VitaGraft™ assay significantly reduces diagnosis time for kidney transplant rejection in high-risk patients.Quiver AI SummaryOncocyte Corp. has announced favorable results...

OCX : 2.19 (-0.90%)
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms  GlobeNewswire - Mon Dec 2, 3:05PM CST

OCX : 2.19 (-0.90%)
OncoCyte: Q3 Earnings Snapshot AP - Tue Nov 12, 3:50PM CST

OncoCyte: Q3 Earnings Snapshot

OCX : 2.19 (-0.90%)
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 GlobeNewswire - Tue Nov 12, 3:05PM CST

OCX : 2.19 (-0.90%)
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 GlobeNewswire - Wed Nov 6, 3:45PM CST

OCX : 2.19 (-0.90%)
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles GlobeNewswire - Wed Oct 16, 3:15PM CDT

OCX : 2.19 (-0.90%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot